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CMS Quality Indicator Initiatives Series
Part V: Surgical Care Improvement Project
By: Lindsey McGrath, PharmD
Pharmacy Practice Resident
Health care is always a top priority in this country and often the
topic of discussion and debate.
In 2004, Medicare spent $300
billion on health care costs, making it the largest purchaser of
healthcare in the nation.1
In an effort to improve the quality of health care and decrease
costs, the Department of Health
and Human Services (DHHS)
and the Centers for Medicare
and Medicaid Services (CMS)
have joined to create a program
called the Quality Initiative. The
purpose of the Initiative is to encourage health care providers to
enhance the quality of care by
providing financial incentive and
to empower consumers with
quality of care information to
make more informed decisions
about their health care.
The details regarding the initiative are described in the March
2007 issue of the newsletter,
which can be found on the Formulary and Drug Information
Resources Web page.
This month the focus will be the
surgical care improvement pro-

ject (SCIP). Despite significant
improvements in both perioperative patient care and surgical and
anesthesia techniques, the incidence of postoperative complications ranges from 6 to 30%, and is
highly variable between both patients and institutions. The most
common surgical complications
associated with increased hospital
length of stay, hospital costs, and
patient mortality include the following: surgical site infections
(including sepsis), cardiovascular
and respiratory complications, and
thromboembolic events.
A recent report from the privatesector National Surgical Quality
Improvement Project (NSQIP)
compared hospital costs for patients who develop surgical complications to those patients who
experience no complications.
Their results suggest that patients
developing postoperative complications stay in the hospital 9 to 14
days longer than patients without
complications. In addition, the
NSQIP report demonstrated that
the increased hospital costs per
patient for postoperative complications are $1,398 for infectious
complications, $7,789 for cardio-
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vascular complications, $18,310
for thromboembolic events, and
$52,466 for respiratory complications.
In April 2003, CMS and the Centers for Disease Control and Prevention (CDC), together with several other national organizations,
initiated a national partnership
dedicated to reducing surgical
complications and mortality. The
primary objective of SCIP, is to
reduce preventable surgical morbidity and mortality by 25% before 2010. In order to accomplish
this objective, the partnership has
developed several quality improvement measures aimed to reduce infectious, cardiovascular,
and thromboembolic complications.
Currently, CMS and the Joint
Commission (JC) recognize 6 core
measures that target infection prevention:
▪ prophylactic antibiotic therapy 1
hour prior to incision (2 hours

▪
▪

▪

▪
▪

for vancomycin and flouroquinolones).
appropriate antibiotic selection
for surgical patients.
prophylactic antibiotic therapy
discontinued within 24 hours
of surgery (48 hours for cardiac surgeries).
controlled 6 AM glucose
measurement for cardiac surgery patients.
appropriate hair removal prior
to surgery.
immediate postoperative normothermia for colorectal surgery patients.

On June 21, 2005, CMS and JC
announced that data collection
for the quality measure, appropriate antibiotic selection for
surgical patients, was temporarily postponed. During this time,
a panel of experts convened to
address controversial topics including the increasing prevalence of methacillin resistant
Staphylococcus aureus (MRSA),

Table 1. Performance Measures for the National Surgical
Improvement Project (SCIP)
Preventative
Performance Measures
Category
▪ Antimicrobials 1 hour prior to surgical incision1
▪ Antimicrobial choice consistent with national
2

guideline recommendations
Surgical Site
Infection

Venous
Thromboembolism (VTE)
Cardiac
Events
1

▪ Antimicrobial discontinued within 24 hours of
▪
▪
▪
▪
▪

surgery end3
Blood glucose control in cardiac surgery patients
Appropriate hair removal prior to surgery
Maintenance normothermia in colorectal surgery
VTE prophylaxis consistent with national guidelines4
VTE prophylaxis administered within 24 hours
after surgery end

▪ Perioperative β-blocker therapy for patients receiving
β-blockers prior to surgery

Flouroquinolones and vancomycin should be given 2 hours before incision
American Society of Health-System Pharmacists, Infectious Diseases Society, CDC, and the Surgical Infection Society
48 hours for cardiac surgeries
4
CHEST. 2004;124:338S-400S
2
3

national drug shortages, and recommendations for endocarditis
prophylaxis. These proceedings
resulted in the following quality
measurement modifications:
▪ in the absence of a β-lactam allergy, physician justification for
prescribing vancomycin must be
documented in the patient’s
chart.
▪ due to the national shortages of
cefotetan and cefoxitin, ampicillin/sulbactam is now considered
an appropriate agent for hysterectomy and colorectal surgeries.
▪ antibiotics recommended for
endocarditis prophylaxis should
include an agent with Enteroccocus coverage such as ampicillin/sulbactam; clinicians may
choose to add an additional single dose of gentamicin.
National data collection reflecting
these new recommendations resumed July 1, 2006. These additional antibiotic recommendations
are based on guidelines published
by the American Society of
Health-System Pharmacists, Infectious Diseases Society, CDC, and
the Surgical Infection Society
(Table 2).
Preventing cardiac complications
in surgery patients is the second
major focus of the SCIP steering
committee. Surgery patients who
develop cardiac complications
have prolonged hospitalizations,
increased hospital costs, and have
a 60% increase risk of mortality
per cardiac event. Acute myocardial infarction, sudden cardiac
death, and pulmonary edema occur in 2 to 5% and up to 30% of
patients undergoing noncardiac
and cardiac surgeries, respectively. Data collection for a new
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Table 2. Preferred Antimicrobials for Surgical Prophylaxis
Surgery
Cardiac
CABG
Vascular
Hip/Knee
Arthroplasty

Hysterectomy

Preferred Antimicrobial

β-lactam Allergy

cefazolin, cefuroxime,
or vancomycin*

clindamycin or
vancomycin

cefazolin, cefuroxime,
or vancomycin*

clindamycin or
vancomycin
clindamycin + gentamicin or
flouroquinolone or aztreonam
OR
metronidazole + gentamicin or
flouroquinolone
OR
clindamycin monotherapy

cefotetan, cefazolin,
cefoxitin, cefuroxime, or
ampicillin/sulbactam

Oral
neomycin sulfate + erythromycin
base or metronidazole
Colon

*

Intravenous
cefotetan, cefoxitin, or
ampicillin/sulbactam
OR
cefazolin + metronidazole

clindamycin + gentamicin or
flouroquinolone or aztreonam
OR
metronidazole + gentamicin or
flouroquinolone

Physician must document justification for vancomycin use in patient chart

quality
indicator,
continuing
β-blocker therapy in patients
previously on β-blockers prior
to admission, began July 1, 2006.
Finally, the third area of focus for
SCIP is prevention of venous
thromboembolism. Without prophylactic medications, pulmonary
embolism and deep-vein thrombosis occurs in 7% and 25% of major surgeries, respectively. National data audits reflect that venous thromboembolism prophylaxis is underused, underdosed,
and is not being prescribed in the
appropriate surgical populations.
Two new quality improvement
measures include initiation of venous thromboembolism prophylaxis in appropriate surgery pa-

tients (CHEST. 2004;124:338S-400S)
and initiation of venous thromboembolism prophylaxis within
24 hours prior to surgery to 24
hours after surgery. Data collection for these measures began
July 1, 2006.
Data reflecting how well the surgical services at the Medical
University of South Carolina
(MUSC) comply with the recommended quality improvement
measures have been published
for January to June 2006 and
July to September 2006 (Table
3). The only measure reflecting
100% compliance was controlled
6 AM glucose measurements in
cardiac surgery patients. Measures achieving greater than 90%

compliance include antibiotics
within 1 hour of incision and
proper hair removal. Areas for
improvement include antibiotic
selection, antibiotics discontinued
within 24 hours of surgery, and
postoperative normothermia for
colorectal surgeries. Data reflecting MUSCs compliance with the
new cardiac and venous thromboembolism measures have not
yet been published, but will be
included in the data analysis for
the next quarter (Table 3).
In order to increase compliance
with surgical quality improvement
measures within our institution, a
team approach comprised of
nurses, physicians, and pharmacists is necessary. Everyone in-
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volved in patient care needs to be
aware of the quality indicators and
educated of their role in the SCIP.
For example, it may be the role of
nurses to assure appropriate patient allergy documentation in
charts. Recommendations to improve compliance include development of pre-printed surgical
order forms and staff education
sessions. Finally, proper documentation is required to pass quality measures and is the role of
every health-care professional.

Guidelines and Policies:
New Additions and
Revisions
The Guidelines for the Management of Neutropenic Infections in
Hematology/ Oncology and Stem
Cell Transplant Patients have
been updated to reflect current
practices. The guidelines contain
information regarding principle of
neutropenia and appropriate practice, including: evaluation of the
patients, laboratory/radiology testing, special consideration, appropriate antibiotic use, and specific
formulas for dosing calculations.
The guidelines can be found on
the Formulary and Drug Information Resources Web page under
Drug Information Resources. The
direct link is listed as reference 1.
The Guidelines for the Use of Colony-Stimulating Factors (CSFs)
was recently developed to guide
appropriate prescribing for use in
primary and secondary CSF prophylaxis in patients receiving chemotherapy or in patients who develop grade 3 or 4 neutropenia
following chemotherapy.
The
guidelines can be found on the
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Table 3. MUSC Results for Quality Indicator Measures
Core Measure

July - September
2006

October - December
2006

91%

95.2%

77%

89.7%

86%

83.5%

100%

96.8%

92%

93.6%

67%

56.3%

New

87.5%

New

87.5%

New

86.1%

Prophylactic antibiotics received 1 hour prior to incision*
Appropriate prophylactic
antibiotic selection
Prophylactic antibiotics discontinued within 24 hours of
surgery (48 hours for cardiac
surgeries)
Controlled 6 AM glucose in
cardiac surgery patients
Appropriate hair removal
Immediate postoperative normothermia for colorectal
surgery patients
β-blocker therapy continuation
in patients receiving β-blocker
prior to admission
VTE prophylaxis in recommended surgery patients
Initiation of VTE prophylaxis
within 24 hours prior to or 24
hours after surgery

* Flouroquinolones and vancomycin should be given 2 hours before incision

The

MED•U•WAY
To Care For Patients
*** An MUSC Lecture Series***

The next MED•U•WAY
Conference will focus on e-Care
Net, the MUSC Clinical Record.
The program will be held on
Thursday, June 21, 2007, at
12:00 PM, in 2 West
Amphitheater.
The featured speakers will be
Kenneth Spicer, MD,
Department of Radiology, Chris
Fortier, PharmD, Pharmacy
Support Services, and Pat Aysse,
RN, Perioperative Procedure

System Program Manager.
The speakers will explain features
and functionality of the bar code
medication administration, prescriber order entry, and perioperative clinical systems.
Attendees will receive 1 credit
hour of continuing education, and
lunch is provided.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee.
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FORMULARY UPDATE FOR MAY 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below.
The formulary effective date will
be June 14, 2007.
Not Added:
The 750-mg cephalexin (Keflex®)
capsule was requested for addition
due to the potential for less medication errors as well as a more
convenient dosage form. Currently, the 250- and 500-mg capsules are on the formulary. The
750-mg capsule is only available
as the brand-name product; therefore, three 250-mg capsules are
less expensive to administer than
the one 750-mg capsule.
Line Extensions:
Infuvite Pediatric
Multi-dose vials
Formulary and Drug Information
Resources Web page under Drug
Information Resources. The direct
link is listed as reference 2.

Beclomethasone (QVAR)
40 and 80-microgram inhalers
Enteral Feedings Products
▪ Oxepa® (specialized formula
for patients with ARDS)
▪ Crucial® (replaces Pivot® 1.5
[immune-enhancing formula])
▪ Peptamen® AF (Vital® HN and
Perative®)
▪ Benefiber®
▪ Portagen®
▪ Peptamen Junior® with
Prebio™ (replaces Peptamen
Junior)
Automatic Therapeutic Substitution (ATS) Protocol:
Orders written for fluticasone
(Flovent® HFA) in patients requiring mechanical ventilation,
having a tracheotomy tube, or
requiring a large-volume spacer
will be changed to bepartments were concerned about
the documentation of morning
administration within 1 hour of
the 0800 time. Additionally, any
medication that was required to
be given around meal times did
not correlate with actual delivery
of the meals. Therefore, the
SATs have been re-evaluated
and will be changing this summer (see reference 3). Examples
of changes include the previous
time of 0800 for daily dosing
being changed to 0900; mealtime dosing (eg, TID with
meals) being set on the half-hour
(0830 - 1230 - 1730); and spe-

clomethasone (QVAR®) inhaler.
The Flovent® HFA inhaler is incompatible with these devices due
to the dose counter on the product.
The protocol will be located on
the Formulary and Drug Information Resources Web page
(www.formularyproductions.com/musc).
Deleted:
M.V.I Pediatric
10-mL vials
Enteral Products
▪ Vital® HN
▪ Pivot® 1.5
▪ Perative®
▪ Traumacal® [Nepro® (on formulary) replaces Traumacal®]
▪ Peptamen® Junior

cific times set for respiratory therapy. These changes will be effective on July 1, 2007.

Based on data collection from
SCIP, it was noted that the abbreStandard administration times
viation NPO was interpreted in
(SATs) have been an established
different ways. Therefore, the
part of medication administration
definition of NPO was standardat MUSC. Recently, with the deized to mean the following: Spevelopment of the AdminRx bar
cial dietary orders, namely orders
code scanning and electronic
for “nothing by mouth” or “NPO,”
medication administration record
are defined strictly as “nothing by
(MAR), the times associated with
mouth.” Unless specifically writthe SATs were evaluated. Most of
the SATs revolve around a mornten, medications will not be given
during the “NPO” period. This
ing administration time of 0800.
period will end when a new diet
Nursing and other ancillary deorder is written. This
Guideline and Policies References:
definition will be added
1. http://www.musc.edu/pharmacyservices/clinsvc/hemeonc/Febrile_Neutropenia2007guidelines.pdf
to Policy C-78: Medica2. http://www.musc.edu/pharmacyservices/clinsvc/hemeonc/CSFs_Guidelines2007.pdf
tion Orders.
3. http://www.musc.edu/pharmacyservices/medusepol/SATimes.pdf

